Abstract
At least 20% of breast cancers are characterized by triple-negative receptor status (negative for estrogen receptor, progesterone receptor, and HER2). Human epidermal growth-factor receptor (EGFR) is a member of the EGFR/ErbB/HER family of Type I transmembrane tyrosine kinase receptors. Nine patients had TN-EGFR-positive with metastatic breast cancer (MBC). EGFR positivity was defined as staining in >10% of tumor cells by Immunohistochemistry. In total, nine patients were enrolled that the mean age was 46.7 years. All patients were from Kurdish ethnicity in west of Iran. Patients received erlotinib 150 mg daily. This suggests there may be a subset of TN, EGFR-positive MBC for whom EGFR-directed therapy may be suitable or that the natural history of their disease was indolent. Future studies to determine molecular and clinical profiles of patients likely to benefit from EGFR-tyrosine kinase inhibitor therapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
